POSC48 Cost-Effectiveness Analysis of Ferric Carboxymaltose Versus Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Spain

Abstract

Iron deficiency anemia (IDA) subsequent to inflammatory bowel disease (IBD) can result in reduced quality of life and increased healthcare costs. IV iron represents the first-line treatment option for many patients. In Spain, ferric carboxymaltose (FCM) and iron sucrose (IS) are the currently available IV iron formulations. This study assessed the cost-effectiveness of FCM compared with IS, in terms of additional cost per additional responder in patients with IDA subsequent to IBD in the Spanish setting.